Pharmacodynamic effects of EV-077: Results of an in vitro pilot investigation in healthy volunteers

Journal of Thrombosis and Thrombolysis

Volumn 34, Issue 3, 2012, Pages 297-299

  Tello Montoliu, Antonio ^a   Rollini, Fabiana ^a   Desai, Bhaloo ^a   Pasqualino, Giuseppe ^a   Patel, Ronakkumar ^a   Sorensen, Alexandra Santana ^b   Sakariassen, Kjell S ^c   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EVOLVA SA   (Switzerland)

^c KellSa sas   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EV 077; THROMBOXANE A2 RECEPTOR; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; INFORMED CONSENT; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; VOLUNTEER;

ATHEROSCLEROSIS; BLOOD PLATELETS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 84868477095     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0795-6     Document Type: Article

References (13)

1. Ueno M, Kodali M, Tello-Montoliu A, Angiolillo DJ (2011) Role of platelets and antiplatelet therapy in cardiovascular disease. J Atheroscler Thromb 18:431-442
2. Moncada S, Vane JR (1978) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30:293-331
3. Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM, Valentin F, Tippins J, Kinsella BT, Masereel B, Pace-Asciak C, Pirotte B, Dogné JM (2005) In vitro and in vivo pharmacological characterization of BM-613[N-n-pentyl-N′-[2-(4′-methylphenylamino)-5- nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist. J Pharmacol Exp Ther 313:293-301
4. Patrono C, García Rodríguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383
5. Sakariassen KS, Alberts P, Fontana P, Mann J, Bounameaux H, Sorensen AS (2009) Effects of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Fut Cardiol 5:479-493
6. Pratico D (2008) Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis 201:8-16
7. Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer JP, Sorensen AS (2011) The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. J Thromb Haemost 9:2109-2111
8. Sakariassen KS, Muggli R, Baumgartner HR (1989) Measurements of platelet interaction with components of the vessel wall in flowing blood. Methods Enzymol 169:37-70
9. Tello-Montoliu A, Ueno M, Angiolillo DJ (2011) Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Fut Cardiol 7:381-402
10. Angiolillo DJ (2009) Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 103:27A-34A
11. Cipollone F, Rocca B, Patrono C (2004) Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24:246-255
12. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA (2000) The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20:1724-1728
13. Roger S, Pawlowski M, Habib A, Jandrot-Perrus M, Rosa JP, Bryckaert M (2004) Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation. FEBS Lett 556:227-235